Risk-Based Monitoring Approaches for Enhancing Quality and Efficiency in Oncology Clinical Trials

• Author(s): Chisom Ezeanochie ; Opeoluwa Oluwanifemi Ajayi ; Christiana Adeyemi
• Paper ID: 1710571
• Page: 192-213
• Published Date: 31-01-2019
• Published In: Iconic Research And Engineering Journals
• Publisher: IRE Journals
• e-ISSN: 2456-8880
• Volume/Issue: Volume 2 Issue 7 January-2019

Abstract

Risk-based monitoring (RBM) has emerged as a transformative approach to improving the quality and efficiency of oncology clinical trials, where traditional monitoring methods often struggle with complexity, high costs, and operational inefficiencies. In oncology studies, characterized by large patient populations, multiple sites, and intricate therapeutic regimens, RBM provides a structured framework for focusing oversight on areas of highest risk while reducing unnecessary monitoring burden. By integrating centralized data review, key risk indicators (KRIs), and advanced statistical methods, RBM shifts the paradigm from exhaustive source data verification to proactive risk detection and mitigation. This abstract explores the role of RBM in enhancing clinical trial performance, particularly in oncology, by streamlining data integrity processes, improving patient safety oversight, and optimizing resource allocation. It emphasizes how data-driven insights derived from centralized monitoring enable early detection of protocol deviations, adverse events, and data anomalies, thereby ensuring regulatory compliance and patient protection. Additionally, RBM facilitates adaptive trial management by allowing continuous reassessment of monitoring strategies based on evolving trial risks, site performance, and patient recruitment trends. This flexibility is particularly valuable in oncology, where trials often involve complex endpoints, biomarker-driven subgroups, and long-term follow-up requirements. Evidence suggests that RBM can reduce monitoring costs, accelerate decision-making, and improve overall trial quality without compromising regulatory standards. Furthermore, RBM supports broader initiatives toward digital transformation in clinical research by leveraging real-time analytics, remote monitoring technologies, and risk visualization dashboards. These innovations enhance collaboration between sponsors, sites, and regulatory bodies, promoting transparency and accountability. Ultimately, risk-based monitoring is not merely a cost-containment strategy but a quality-driven framework that aligns with global regulatory guidance and the evolving needs of oncology research. Its implementation represents a critical step toward delivering robust, reliable, and patient-centered outcomes in cancer clinical trials, while ensuring efficiency in increasingly complex research environments.

Keywords

Risk-Based Monitoring, Oncology Clinical Trials, Quality Management, Data Integrity, Patient Safety, Efficiency, Centralized Monitoring, Key Risk Indicators, Regulatory Compliance, Adaptive Trial Management.

Citations

IRE Journals:
Chisom Ezeanochie , Opeoluwa Oluwanifemi Ajayi , Christiana Adeyemi "Risk-Based Monitoring Approaches for Enhancing Quality and Efficiency in Oncology Clinical Trials" Iconic Research And Engineering Journals Volume 2 Issue 7 2019 Page 192-213

IEEE:
Chisom Ezeanochie , Opeoluwa Oluwanifemi Ajayi , Christiana Adeyemi "Risk-Based Monitoring Approaches for Enhancing Quality and Efficiency in Oncology Clinical Trials" Iconic Research And Engineering Journals, 2(7)